Background and Aims: Acute severe colitis [ASC] is associated with major morbidity. We aimed to develop and externally validate an index that predicted ASC within 3 years of diagnosis. Methods: The development cohort included patients aged 16-89 years, diagnosed with ulcerative colitis [UC] in Oxford and followed for 3 years. Primary outcome was hospitalization for ASC, excluding patients admitted within 1 month of diagnosis. Multivariable logistic regression examined the adjusted association of seven risk factors with ASC. Backwards elimination produced a parsimonious model that was simplified to create an easy-to-use index. External validation occurred in separate cohorts from Cambridge, UK, and Uppsala, Sweden. 
Introduction
Acute severe colitis [ASC] has well-defined criteria for diagnosis which guide management, the timing of decision making and predicts outcome. 1, 2 The commonest indication for colectomy is ASC unresponsive to medical therapy, and one or more hospital admissions with ASC are associated with an overall risk of colectomy approaching 40%, compared with just 3% in those never hospitalized. 3 Yet in 2015, ASC remains a potentially life-threatening condition. In the UK national audit, the overall mortality of 2981 patients hospitalized with ASC was 1.2%, but reached 1.9% in patients aged 50-59, 3 .5% in those aged 60-69 and over 10% in those aged > 80 years. 4 There is, therefore, a need to identify factors that predict the risk of ASC. Predicting a severe or disabling course of Crohn's disease has received substantial attention in the past decade, deploying clinical criteria, gene expression profiling of CD8 + T cells, or biochemical and endoscopic predictors. [5] [6] [7] In Crohn's disease, predictors can potentially be identified at diagnosis, when they might influence management and outcome [for a review, see reference   7 ]. The same applies to UC, with the advantage that there are simpler endpoints [hospital admission with ASC or colectomy] and a more homogeneous patient population. As a surrogate for a progressive or severe course of UC, the need for immunomodulators was studied in a cohort of 262 patients. 9 A relatively complex six-item model was derived, which predicted the need for immunomodulators within 5 years in 60% of patients, including simple items such as extent, CRP and anaemia. Preliminary examination of genetic factors also led to a risk score for colectomy, based on 46 single nucleotide polymorphisms [SNPs] that accounted for 48% of the variance. 13, 14 From a patient's perspective, however, there are few data that might predict hospital admission, although admission identifies those with a 10-fold higher risk of colectomy. 3 Thresholds for admission vary between countries, but the internationally accepted criteria for diagnosis of ASC and relationship to outcome should supersede national differences. 2, 16 This is an area of unmet need, because it potentially identifies at an early stage those likely to pursue a poor disease course, as treatment options proliferate. The aim of this study, therefore, was to identify predictive factors for developing ASC over a 3-year period from the date of diagnosis of UC, to create a simple index that could be applied in clinical practice, followed by validation in two independent cohorts of patients.
Methods
All patients diagnosed with UC between 2007 and 2010 in Oxford, and followed until September 2013, were used to develop the prediction model. Patients were identified from a registry of patients and centrally located case notes. UC diagnosis was based on standard clinical, endoscopic and histopathological criteria. 2 The primary outcome was ASC needing hospitalization, defined by Truelove andand Witts' criteria 1 
Validation cohorts
The performance of a prediction model can be evaluated using internal and external validation. External validation is the strongest test of a model, as it entails using independent data to evaluate the performance of a model, which we present using data from Cambridge and Sweden. Internal validation, which is used to assess any overfitting, entails evaluating the model on the same population from which the model was developed, using either cross-validation or more efficient bootstrapping [below] . Criteria for inclusion in the two independent cohorts were the same as the development cohort: patients diagnosed and followed up for at least 3 years, excluding those hospitalized with ASC within a month of diagnosis. Patients were identified from contemporary disease registries, without strict adherence to Truelove and Witts' criteria for hospitalization: all those hospitalized met the criteria, but some who met criteria were not admitted.
Statistical methods
Sample size considerations for developing multivariable prediction models are based on the ratio of number of outcome events to the number of risk factors examined, referred to as events per variable [EPV] . A minimum EPV of between 5 and 10 is recommended to avoid overfitting. 21, 22 Consequently analysis was restricted to seven factors: 34 patients in the development cohort were diagnosed with ASC, leading to an EPV of 5. Multiple imputation was used to replace missing values to maximize available information and reduce potential bias introduced by deleting incomplete records [CRP: 24% and 7% missing; Hb 21% and 7% missing in Oxford and Cambridge cohorts, respectively]. There were no missing data in the final model in the Uppsala cohort, reflecting differences between paper and electronic records. Logistic regression was used to investigate contributions for each risk factor to the prediction of ASC. Inclusion of risk factors was pragmatic, rather than statistical significant [notably Hb], based on their likelihood of being recorded at diagnosis and robustness [i.e. least subjective and low likelihood of disagreement in records].
Performance of the prediction model was assessed by examining measures of discrimination and calibration. Discrimination [whether the relative ranking of individual predictions is in the correct order] was quantified by the concordance index [c-index], equivalent to the area under the receiver operating characteristic curve. 23 A c-index of 0.5 indicates no discrimination, whereas a c-index of 1.0 indicates perfect discrimination. Calibration is the accuracy of agreement of the predicted probability of the outcome provided by the model with the observed frequency of the outcome. Internal validation of the prediction model was assessed using bootstrapping, which provided validation through a bootstrap biased-corrected c-index. 24, 25 The entire modelling process was repeated, including variable selection in 200 bootstrap samples with replacement from the original sample.
A simplified index was created by assigning integer points to predictors in the final model. A nomogram [which is simply a graphical representation of the prediction model] to allow individualized risk prediction was developed based on the final logistic regression model for use in clinical practice. All analyses were performed using the R package [version 3.0.1] with the RMS library. We followed TRIPOD guidelines for reporting prediction model studies. 26, 27 3. Results
Patient demographics
Features at diagnosis are shown [ Table 1 ]. Each cohort is separated into patients who were and were not hospitalized for ASC within 3 years from diagnosis. In the Development cohort, out of 1850 patients with UC followed up in Oxford 
Univariate and multivariable logistic regression
Results of univariate and multivariable logistic regression analysis of risk factors in the Development cohort are summarized in Table 2 . Univariate analyses showed no significant difference for age and the significance of histological severity was borderline. All other factors showed statistically significant differences at diagnosis between patients subsequently hospitalized with ASC within 3 years and those not hospitalized.
Multivariable logistic regression confirmed that extent, CRP and haemoglobin were significant predictors of ASC. 13.5 [13, 14] 10.4 [10, 11] 13.9 [13, 15] Oral steroid therapy at diagnosis 
Initial model
The initial multivariable model [which included endoscopy, later discarded, see Methods] showed good discrimination, with a c-index of 0.84. The calibration plot [ Figure 1a ] grouped patients with similar predicted risks into fifths, from lowest to highest risk.
Final prediction model
The final model included three factors: extent of disease, CRP and haemoglobin at diagnosis. The model still showed good discrimination [c-index = 0.77]. Bootstrapping for internal validation showed good calibration [ Figure 1b ].
To create an index of practical value in outpatients, the final predictive index assigned one point for each component: 0ne point for E3 extent of disease, one point for CRP > 10 mg/l and one point for haemoglobin < 14 g/dl [men], or < 12 g/dl [women] . Values were selected for simplicity in practice: the most accurate predictive model identified haemoglobin thresholds of 13.8 g/dl for men and 12.1 g/dl for women, but rounding the numbers enhanced simplicity and did not alter the predictive value. This arbitrary decision is consistent with the goal of creating an index that is simple, potentially memorable and robust. An increasing number of components at diagnosis increased the predicted risk of being hospitalized with ASC within 3 years [ Table 3 and Figure 2 ].
Nomogram for individual risk
In order to calculate individual risk more precisely, a nomogram was constructed [ Figure 3 ] to enable the results for a patient to correspond with predictive points, by reading off the points on the top axis. The points for each component are summed to calculate 'total points', estimating the probability of ASC for the individual patient over the next 3 years from diagnosis by drawing a line down from the 'total points' axis.
Discussion
This study shows that a simple index of three components [extent of disease, CRP and haemoglobin] applied at diagnosis reliably predicts the risk of ASC within the following 3 years in different populations. It implies that extensive, severe disease at diagnosis is associated with a worse prognosis, consistent with clinical experience. It potentially allows objective identification of a group of patients who need intensive monitoring or early intervention with the most effective therapy. The simplicity of the index, using data that are readily available and almost invariably recorded, is particularly appealing.
To create the simplest model that accurately predicted the risk of ASC in 69% of patients after diagnosis in the Development cohort [72% in the external validation cohort in Uppsala], one point was applied to a threshold for each component [extent of E3, CRP > 10 mg/l, and haemoglobin < 14 g/dl for men or < 12 g/dl for women]. This is readily remembered and can be applied in outpatients. The risk score from 0/3 to 3/3 achieved predictive ability and good calibration. It was also possible to develop a more The predictive index performed equally well in all three centres: a score of 3/3 accurately predicted subsequent hospitalization in every patient [18/18] in Cambridge and 93% [12/13] [18/96] , which reflects the population-based cohort in Sweden. This is consistent with it being the biological severity of UC, rather than management strategy or admission threshold, that predicts hospitalization and may account for the low rate of colectomy in the Swedish ICURE cohort [2.5% in the first year after diagnosis], 28 compared with Oxford. 3 Haemoglobin and CRP are biological markers of severity, which gives further reason to believe that the index will have predictive value in practice. Whether the same thresholds apply to patients with UC in populations with a lower haemoglobin [eg India or East Asia] than the West, remains to be established. A key strength was demonstrating good performance of the index in three independent cohorts with different patient characteristics and rates of hospitalization.
There are limitations. Most notably, the study was retrospective, so patients diagnosed in the centres may have been missed or lost to follow-up. Such patients are more likely to have less severe disease. Although retrospective, the criteria are completely objective. Furthermore, external validation of the index in two independent cohorts tested the model. Proportions in Oxford and Cambridge who developed ASC and outcomes with regard to rescue therapy or colectomy are consistent with published data.
3,4,29 A more complex model derived from weighting of individual items after multivariable analysis might have performed better, but predictive models are best kept simple if they are to be used. The index identified 70-100% of patients at diagnosis who were hospitalized for colitis within 3 years, which is sufficient for clinical practice. Data collection excluded details of therapy, because choice constitutes too many variables: not only the drug, dose and duration, but also the individual physician, patient and preference. Nevertheless, steroids at diagnosis in 91% of those who later developed ASC [compared with 35% who did not] in the Development cohort [ Table 1 ] is consistent with the premise that biologically severe disease at diagnosis has a worse outcome. The timing to assess disease extent also varied. Extent was defined at first colonoscopy, but precise timing [dependent on severity and access to colonoscopy] was not captured.
The index lends itself to assessment in an interventional study, since the principal value of an index is not to prognosticate but to guide treatment. Patients who score 3/3 at diagnosis of UC are candidates for early intervention with immunomodulators to reduce the risk of ASC. Effectiveness and safety need testing in a multicentre, randomixed controlled trial. Validation in different populations, including India or East Asia, would be informative. Meanwhile this index can be used to identify patients at diagnosis of UC as at high risk, who may need more proactive management than others. 
Conflict of Interest
None. 
